首页> 外文OA文献 >ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers
【2h】

ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers

机译:ATM,ATR和DNA-PKcs表达与上皮性卵巢癌不良临床预后相关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Ataxia-telangiectasia mutated (ATM), ataxia-telangiectasia mutated and rad3 related (ATR) and DNA-dependent protein kinase catalytic sub-unit (DNA-PKcs) play critical roles in DNA damage response (DDR) by linking DNA damage sensing to DDR effectors that regulate cell cycle progression and DNA repair. Our objective was to evaluate if ATM, ATR and DNA-PKcs expressions could predict response to therapy and clinical outcome in epithelial ovarian cancers. Methods: We investigated ATM, ATR, and DNA-PKcs expressions in ovarian epithelial cancers [protein expression (n = 194 patients), mRNA expression (n = 156 patients)] and correlated to clinicopathological outcomes as well as expression of X-ray repair cross-complementing protein 1 (XRCC1), cell division cycle-45 (CDC45), cyclin-dependent kinase 1(CDK1) and Ki-67 in tumours. Results: High ATM protein expression was associated with serous cystadenocarcinomas (p = 0.021) and platinum resistance (p = 0.017). High DNA-PKcs protein expression was associated with serous cystadenocarcinomas (p = 0.006) and advanced stage tumours (p = 0.018). High ATM protein (p = 0.001), high ATM mRNA (p = 0.018), high DNA-PKcs protein (p = 0.002), high DNA-PKcs mRNA (p = 0.044) and high ATR protein (p = 0.001) expressions are correlated with poor ovarian cancer specific survival (OCSS). In multivariate Cox model, high DNA-PKcs (p = 0.006) and high ATR (p = 0.043) protein expressions remain independently associated with poor OCSS. Conclusions: ATM, ATR and DNA-PKcs expressions may have prognostic and predictive significances in epithelial ovarian cancer. General significance: The data presented here provides evidence that ATM, ATR and DNA-PKcs involved in DDR are not only promising biomarkers but are also rational targets for personalized therapy in ovarian cancer.
机译:背景:共济失调-毛细血管扩张突变(ATM),共济失调-毛细血管扩张和rad3相关(ATR)和DNA依赖性蛋白激酶催化亚基(DNA-PKcs)通过连接DNA损伤传感在DNA损伤反应(DDR)中起关键作用。调节细胞周期进程和DNA修复的DDR效应子。我们的目的是评估ATM,ATR和DNA-PKcs的表达是否可以预测上皮性卵巢癌对治疗的反应和临床结果。方法:我们调查了卵巢上皮癌中的ATM,ATR和DNA-PKcs表达[蛋白质表达(194例),mRNA表达(156例)],并与临床病理结果以及X线修复的表达相关交叉互补蛋白1(XRCC1),细胞分裂周期45(CDC45),细胞周期蛋白依赖性激酶1(CDK1)和Ki-67在肿瘤中的表达。结果:高ATM蛋白表达与浆液性囊腺癌(p = 0.021)和铂耐药(p = 0.017)相关。 DNA-PKcs蛋白的高表达与浆液性囊腺癌(p = 0.006)和晚期肿瘤(p = 0.018)相关。高ATM蛋白(p = 0.001),高ATM mRNA(p = 0.018),高DNA-PKcs蛋白(p = 0.002),高DNA-PKcs mRNA(p = 0.044)和高ATR蛋白(p = 0.001)表达是与较差的卵巢癌特异性生存率(OCSS)相关。在多变量Cox模型中,高DNA-PKcs(p = 0.006)和高ATR(p = 0.043)蛋白表达仍然与不良OCSS独立相关。结论:ATM,ATR和DNA-PKcs的表达在卵巢上皮癌中可能具有预后和预测意义。一般意义:此处提供的数据证明DDR中涉及的ATM,ATR和DNA-PKcs不仅是有前途的生物标志物,而且还是卵巢癌个性化治疗的合理靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号